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Abstract: Background and Objectives: Hyperbaric oxygen is a recognised treatment for a range of
medical conditions, including treatment of diabetic foot disease. A number of studies have reported
an impact of hyperbaric oxygen treatment on glycaemic control in patients undergoing treatment
for diabetic foot disease. There has been no systematic review considering the impact of hyperbaric
oxygen on glycaemia in people with diabetes. Materials and Methods: A prospectively PROSPERO-
registered (PROSPERO registration: CRD42021255528) systematic review of eligible studies published
in English in the PUBMED, MEDLINE, and EMBASE databases, based on the following search terms:
hyperbaric oxygen therapy, HBO2, hyperbaric oxygenation, glycaemic control, diabetes, diabetes
Mellitus, diabetic, HbA1c. Data extraction to pre-determined piloted data collection form, with
individual assessment of bias. Results: In total, 10 eligible publications were identified after screening.
Of these, six articles reported a statistically significant reduction in blood glucose from hyperbaric
oxygen treatment, while two articles reported a statistically significant increase in peripheral insulin
sensitivity. Two articles also identified a statistically significant reduction in HbA1c following
hyperbaric oxygen treatment. Conclusions: There is emerging evidence suggesting a reduction in
glycaemia following hyperbaric oxygen treatment in patients with diabetes mellitus, but the existing
studies are in relatively small cohorts and potentially underpowered. Additional large prospective
clinical trials are required to understand the precise impact of hyperbaric oxygen treatment on
glycaemia for people with diabetes mellitus.
Keywords: diabetes; hyperbaric oxygen therapy; glycaemia
1. Introduction
The use of hyperbaric oxygen in treating decompression sickness in deep-sea divers
and people with carbon monoxide poisoning is well-established [1]. Hyperbaric oxygen
therapy (HBOT) is also an approved medical treatment for various conditions including
necrotizing soft tissue infection, diabetic wounds, osteomyelitis, compartment syndrome,
crush and reperfusion injuries, and acute sensorineural hearing loss [1]. HBOT has been
postulated to have a positive impact on diabetic foot ulcers, suggesting its incorporation as
an adjunct treatment with further scope for research in this area [2,3].
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HBOT involves oxygen delivery at a concentration of 100% with a pressure of 2 to 3
atmosphere absolute (ATA) in a hyperbaric chamber. The mechanism of HBOT is to
increase tissue oxygen levels resulting in accelerated wound healing, decreased oedema,
and killing of anaerobic bacteria [4,5].
In diabetes, meticulous glycaemic control has been shown to reduce the risk of mi-
crovascular, macrovascular, and neurological complications [6,7]. There is emerging ev-
idence demonstrating blood glucose level changes in people with diabetes undergoing
hyperbaric oxygen treatment [8–12]. However, these studies have involved diverse method-
ologies, whilst, to date, there has been no systematic review of the impact of HBOT on
glycaemia in people with diabetes.
Here, we present the first systematic review considering the effect of HBOT on the
glycaemia in people with diabetes. We also explore the proposed mechanisms involved in
the potential impact of HBOT on glycaemia in diabetes.
2. Materials and Methods
The systematic review was performed according to the PRISMA protocol as shown in
Figure 1 [13]. The review was prospectively registered on the NIHR PROSPERO Database
(PROSPERO registration ID: CRD42021255528).
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2.1. Study Selection
The literature search was conducted in the PUBMED, MEDLINE, and EMBASE databases.
The search terms used to identify the relevant medical literature were Hyperbaric oxygen
ther py/HBO2/hyperbaric oxygenation; Glycaemic control; Diabetes/diabetic/diabetes
mellitus; HbA1c. The search strategies used are detailed in the Appendix A(Tables A1–A3).
Only studies involving humans whichwere published in English language journals were
considered eligible, with no restriction to the publication date. Furthermore, filters were
applied to set participant’s age as 18 years and above, as this research looked at only the
adult population with any type of diabetes (excluding diabetes insipidus) who had under-
gone HBOT. Any study that focused only on animals, children, or hyperbaric combination
therapies was excluded. Any studies focusing on wound care and insulin sensitivity were
also excluded. Studies focused on insulin sensitivity but mentioning glycaemia as an
outcome in their abstracts were included.
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2.2. Data Extraction
Data were extracted to a pre-defined, data-extraction proforma which was based
on the following variables: year of publication, type of study, location of research and
publication, sample size including the baseline characteristics of the population, any biases,
single centre or multicentre study, length of follow up comprising of a number of session
of interventions, statistical methods used for analysis showing the statistically significant
outcome. Miscellaneous variables relevant to this systematic review were also extracted.
Data extraction was performed independently by two authors (S.B. and A.P.), with any
discrepancies resolved by a third author (T.R.).
2.3. Quality Assessment
All studies included in the review were assessed for study quality. Due to the small
number of studies and diverse methodologies a single formal tool was not used. Instead, a
narrative review was conducted for bias considering sample size, study methodology, any
evidence of randomisation, and blinding. All studies were assessed independently for bias
by two authors (S.B. and A.P.). Papers were not excluded based on producing a negative
outcome or being of low-quality.
2.4. Data Synthesis
The diversity among the identified eligible studies, in terms of their study design,
sample size and population, did not allow a meta-analysis to be conducted. A qualitative
analysis and narrative summary of the studies reporting any change or any factors that
pre-dispose to changes in HbA1c were performed. Where possible, these changes have
then been grouped under broader categories in a tabulated form.
3. Results
The performed systematic search yielded 428 records. Of these, 208 were duplicates and,
thus, were removed prior to screening of titles and abstracts. Of the 220 records screened,
11 articles were selected for a detailed review. One of these was excluded after detailed review
as it was a letter to editor and not an original research article [10]. In total, 10 studies were
eligible for inclusion in this systematic review, which were all available as full text articles. The
designs and locations of these studies are summarised in Tables 1 and 2. The characteristics
and findings of the individual eligible studies are summarised in Table 3.
Table 1. Summary of study designs included in this systematic review.
Study Design Number of Studies Percentage of Studies (%)
Prospective cohort 7 70
Randomised placebo-controlled trial 1 10
Retrospective analysis 2 20
Table 2. Summary of locations (countries) of the studies included in this systematic review.
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Table 3. Summary of the characteristics and findings of the ten eligible original research studies included in this review. DM = Diabetes Mellitus HTN = Hypertension, HBOT = Hyperbaric
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Of the included studies, seven were prospective studies in cohorts of patients with
diabetes, two presented retrospective analyses of prospectively collected data, and one
study was a randomised, prospective, placebo-controlled trial in patients with type 2
diabetes mellitus. Most of these studies included participants with diabetes mellitus who
were receiving HBOT for various indications, including non-healing wounds, diabetic foot
ulcers, radio-induced cystitis and neurological deficits such as sudden deafness.
The majority of the included studies demonstrated a reduction in blood glucose levels
following a single session of HBOT in patients with type 2 diabetes mellitus. This effect was
consistent across different session lengths and treatment conditions used in the different
studies. A prospective cross-over study by Ekanayake & Doolette demonstrated that
blood glucose levels in five patients with diabetes mellitus reduced following exposure to
both hyperbaric and normobaric conditions, but this decrease only reached significance
following exposure to HBOT for at least 45 min [12]. However, this study did not find a
significant reduction in blood glucose levels in control subjects without diabetes mellitus
in either condition. A significant reduction in blood glucose following a HBOT session in
patients with diabetes mellitus was also shown in a prospective study conducted by Trytko
& Bennett, which assessed mean blood glucose change across up to 10 consecutive HBOT
sessions per participant [9]. This study analysed 226 HBOT sessions across 27 patients, and
reported that there was a decrease in blood glucose levels in 80 of the 102 sessions which
were in patients with type 2 diabetes mellitus. A prospective cohort study in 23 patients
with diabetes mellitus by Al-Waili et al. also demonstrated significant reduction in blood
glucose levels as a mean across 15–30 HBOT sessions per participant [19]. Peleg et al. also
showed statistically significant decrease in blood glucose levels after a HBOT session in
patients with type 2 diabetes mellitus [11], while no significant reduction in blood glucose
levels was noted in healthy volunteers without diabetes following HBOT, agreeing with the
earlier findings by Ekanayake & Doolette. Moreover, the study by Peleg et al. did not find
any significant reduction in blood glucose levels in patients with type 1 diabetes mellitus
following exposure to both hyperbaric and normobaric conditions. A retrospective review
by Heyboer et al. also found a greater impact of HBOT in patients with type 2 diabetes
mellitus as opposed to those with type 1 diabetes mellitus [8]. This retrospective review
of prospectively collected data showed that blood glucose levels in patients with diabetes
mellitus decreased in 75.4% of 1825 HBOT cycles surveyed. However, on further analysis,
a statistically significant greater percentage of treatments of patients with type 2 diabetes
mellitus resulted in a decrease in blood glucose levels (77.5%) compared to treatments of
patients with type 1 diabetes mellitus (51.5%).
Contrary, the study by Stevens et al. does not support this general finding of a
reduction of blood glucose in patients with type 2 diabetes mellitus following HBOT [17].
This retrospective review of prospectively collected data from 190 patients with diabetes
mellitus found that in-chamber glucose was higher than pre-HBOT glucose in 54% of
sessions. However, there is no evidence in this study of statistical analysis of change in
blood glucose levels following HBOT.
The potential mechanism for a reduction in blood glucose levels caused by HBOT
appears to be mediated by increased insulin sensitivity, as opposed to enhanced insulin
secretion. The study by Ekanayake & Doolette measured insulin levels in patients with
diabetes mellitus during both a single session under hyperbaric and normobaric conditions,
and found no change in insulin levels following treatment in either condition [12]. This
finding was also seen in the study by Wilkinson, Chapman & Heilbronn; demonstrating that
there was no change in fasting insulin levels measured in five patients with type 2 diabetes
mellitus even after 30 sessions of HBOT performed over five weeks [18]. This study also
demonstrated a statistically significant increase in peripheral insulin sensitivity after both
3 and 30 sessions of HBOT measured using a hyperinsulinaemic clamp in those patients
with type 2 diabetes mellitus. A further study by Xu et al. subjected 23 patients with type 2
diabetes mellitus to 30 sessions of either hyperbaric or normobaric conditions and assessed
peripheral insulin sensitivity using hyperinsulinaemic-euglycaemic clamps [15]. This study
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also demonstrated a significant increase in peripheral insulin sensitivity in patients with
type 2 diabetes mellitus after 30 HBOT sessions, which was not seen in those exposed to
normobaric conditions. However, this study also showed a significant decrease in insulin
levels after 30 sessions in both HBOT and normobaric condition groups. This evidence
further supports HBOT-induced increased insulin sensitivity as the proposed mechanism
for reducing blood glucose levels in patients with type 2 diabetes mellitus.
The reduction in blood glucose levels in patients with type 2 diabetes mellitus at-
tributed to HBOT appears to be longitudinal. The study by Xu et al. demonstrated a
significant reduction in fasting plasma glucose after 30 sessions of HBOT [15]. A study by
Vera-Cruz et al., which measured fasting plasma glucose and performed an oral glucose
tolerance test (OGTT) at baseline and after 20 sessions of HBOT over four weeks, found
that whilst fasting plasma glucose did not significantly decrease, there was a significant
decrease in glycaemia following an OGTT after 20 sessions of HBOT in patients with type
2 diabetes mellitus [16]. Similarly, Wilkinson, Chapman & Heilbronn also showed no
significant reduction in fasting plasma glucose after 30 sessions of HBOT [18].
HbA1c was used as an outcome measure in three studies following up participants
after multiple sessions of HBOT. The study by Trytko & Bennett found that in 17 patients
with type 2 diabetes mellitus who completed 10 sessions of HBOT, there was a small,
non-significant reduction in HbA1c [9]. The study by Wilkinson, Chapman & Heilbronn
also found no significant change in HbA1c after 30 sessions of HBOT [18]. However, the
study by Xu et al. demonstrated a significant reduction in HbA1c after 30 sessions of HBOT,
which was not seen in those exposed to normobaric conditions [16]. The study by Irawan
et al. corroborates this finding of a reduction in HbA1c, with a significant reduction after
10 HBOT sessions [14].
Some studies suggest that the reduction in blood glucose levels in patients with type
2 diabetes mellitus following HBOT may be independent of the hyperbaric conditions.
Peleg et al. found that there was a significant decrease in blood glucose for patients
with type 2 diabetes after a session under normobaric control conditions [11]. Ekanayake
& Doolette also identified a decrease in blood glucose levels following a session under
normobaric conditions. However, this decrease did not reach significance [12]. Both of
these studies had relatively small participant numbers and only considered the change in
blood glucose after a single session. On the contrary, Xu et al. did not find any change in
fasting plasma glucose or HbA1c after 30 sessions under control normobaric conditions [15].
This study by Xu et al. had a larger number of participants and considered the longitudinal
impact on glycaemia after multiple sessions. The outcomes measured by Xu et al. could
therefore be considered more reliable when considering the clinical utility of HBOT in
type 2 diabetes mellitus as a treatment adjunct. However, these discrepancies highlight
the need for further controlled trials with larger participant numbers to ascertain the
true impact of HBOT on glycaemia in patients with type 2 diabetes mellitus compared to
normobaric conditions.
Moreover, four of the studies do have a consideration for the incidence of hypogly-
caemic events during or immediately after HBOT. The retrospective review by Heyboer et al.
found that none of the patients with diabetes mellitus experienced a hypoglycaemic episode
following a HBOT session [8]. However, the retrospective review by Stevens et al. found
an incidence of 1.5% for hypoglycaemia during or immediately after HBOT in the 3136 ses-
sions reviewed, but noted that severe or symptomatic hypoglycaemic events were rare [17].
The prospective study by Trytko & Bennett had symptomatic hypoglycaemia occur in 11
out of 237 HBOT treatments in patients with diabetes mellitus; only two of these occurring
in patients not requiring insulin treatment [9]. Al-Waili et al. also reported occurrences
of symptomatic hypoglycaemic episodes in two of the 41 study participants undergoing
HBOT; one of these being an insulin-treated diabetes mellitus patient [19]. Patients with
type 1 diabetes mellitus are at an increased risk of hypoglycaemic episodes with HBOT, as
found in the study by Stevens et al. and suggested by the results of the Trytko & Bennett
study [9,17]. A suggestion is made for a threshold blood glucose level below which the
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risk of hypoglycaemia during HBOT is increased, with Al-Waili et al. noting this threshold
level to be 120 mg/dL, whilst the data from Stevens et al. suggesting that this threshold
blood glucose level is 150 mg/dL [17,19].
There are a number of sources of bias to consider when interpreting these studies. The
most significant would be the presence of sampling bias. Moreover, most of the studies
included for analysis in this review had relatively small sample sizes. Even those with large
numbers of HBOT sessions often sourced these from a small number of participants. The
small sample sizes used may reduce the reliability of the obtained results and the external
validity of the reported findings. These small sample sizes may have also impacted the
power of the studies to identify significant changes in glycaemic variables, such as HbA1c,
which HBOT may impact in the longer-term.
A number of the studies included patients with both type 1 and type 2 diabetes
mellitus that were analysed together in a single diabetes mellitus group. Evidence presented
suggests that the effects of HBOT on blood glucose differ between type 1 and type 2 diabetes
mellitus when the subgroups are analysed. Therefore, including both patients with type 1
and type 2 diabetes together may impact the demonstrated effects of HBOT.
The patients included in the majority of these studies received HBOT for treatment
of diverse conditions. Common indications for HBOT included non-healing ulcers and
diabetic foot ulcers. These indications for HBOT can be associated with poorly controlled
diabetes mellitus or long-standing disease, with most studies also having an older age
range of participants. These factors could also have an effect on the impact of HBOT
on glycaemia.
Another source of bias to consider is that the identified studies have included differ-
ent HBOT protocols. This included different hyperbaric conditions, different lengths of
treatments, and different numbers of treatment sessions per patient. Heyboer et al. have
adjusted for this by using each treatment as a unit of analysis as opposed to each partici-
pant [8]. Al-Waili et al. and Trytko & Bennet have taken this into account by measuring the
mean for each patient as the unit of analysis [9,19]. Trytko & Bennet also found that mean
blood glucose reduction following treatment did not significantly alter with treatment
number during the course. However, the methodology used by Peleg et al. suggests that
the number of treatment sessions is an important factor. Peleg et al. suggest that factors
such as anxiety when first introduced to the chamber environment may act as a confound-
ing factor, and so recruited only patients who had already received at least 10 sessions of
HBOT to limit this [11]. Ekanayake & Doolette incorporated a similar principle into their
methodology for the same reason, only sampling blood glucose and insulin on the third
to fifth day of HBOT [12]. Indeed, the findings from the study by Xu et al. also suggest
that the number of treatment sessions is influential, with significant changes in insulin
sensitivity, HbA1c and fasting plasma glucose only after 30 session of HBOT [15]. Whilst
an increase in insulin sensitivity and decreases in fasting plasma glucose and HbA1c were
also observed after 10 sessions of HBOT, these changes were not significant.
Finally, two of the prospective studies were cross-over in design [11,12]. Ekanayake &
Doolette had all participants exposed to control normobaric conditions on the day of their
HBOT session. Peleg et al. had all participants receive their HBOT session before their
normobaric session between 1–14 days later. Randomising the sequence of exposures for
participants may have helped to ensure that the sequence of exposures is not influencing
the results seen.
4. Discussion
The impact of HBOT on glycaemia in people with diabetes mellitus is an area of
contention as demonstrated by several published studies [8–12]. This review represents
the first systematic review conducted on the published research literature to explore the
potential impact of HBOT on glycaemic control in people with diabetes. A total of 10 studies
were eligible to be included in this systematic review which comprised of seven prospective
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cross-over and cohort studies; two retrospective reviews of prospectively collected quality
data; and one randomised, prospective, placebo-controlled trial.
The majority of the studies demonstrated a reduction in blood glucose levels following
HBOT in patients with diabetes, mainly for people with type 2 diabetes mellitus [8,9,15]. The
nine original studies reviewed showcased various results involving different methodolo-
gies. Variables observed included the use of HBOT and normobaric conditions in people
with diabetes mellitus (mainly those with type 2 diabetics mellitus) with assessment of
changes in insulin levels, insulin sensitivity, OGTT, and HbA1c (Table 4). Whilst most of
the studies support the hypothesis that HBOT reduces blood glucose levels in patients
with type 2 diabetes mellitus, there was one study that demonstrated high in-chamber
glucose levels contrasting the other study findings [17]. Blood glucose levels, both basal
and following an OGTT, were also reduced in people with type 2 diabetes mellitus after
several sessions of HBOT [18,19]. Whilst some studies did show a significant reduction in
HbA1c following HBOT, the impact seen was not consistent [9,14,15,18]. This highlights
the need for large prospective trials to ascertain the precise longer-term effects of HBOT on
glycaemia in people with type 2 diabetes mellitus.















2019 Heyboer et al. [8] Decrease * NA NA NA NA
2018 Irawan et al. [14] NA NA NA NA Decrease *
2017 Xu et al. [15] Decrease * Decrease * Increased * NA Decrease *
2015 Vera-Cruz et al. [16] Decrease NA NA Decrease * NA
2015 Stevens et al. [17] Increase † NA NA NA NA
2013 Peleg et al. [11] Decrease * NA NA NA NA
2012 Wilkinson et al. [18] No change No change Increased * NA No change
2006 Al-Waili et al. [19] Decrease * NA NA NA NA
2003 Trytko & Bennet. [9] Decrease * NA NA NA Decrease
2001 Ekanayake &Doolette. [12] Decrease * No change NA NA NA
* Indicates statistical significance. † There is no evidence in this study of statistical analysis of change in blood glucose levels following
HBOT. OGTT = Oral Glucose Tolerance Test, HbA1c = Glycated haemoglobin. Green background colour indicates a positive impact, red
background colour indicates a negative impact and an orange background colour indicates no impact.
The mechanism responsible for the reduction in blood glucose levels caused by HBOT
appears to be, at least in part, attributed to increased insulin sensitivity as opposed to
enhanced insulin secretion, with two studies demonstrating a significant increase in pe-
ripheral insulin sensitivity [15,18]. This finding was particularly noted for people with type
2 diabetes mellitus.
This review has several strengths. These include prospective Prospero registration,
independent two author identification, and extraction, a rigorous PRISMA-based approach
to reporting, an individualised approach to quality assessment of each paper, no restriction
to publication date.
However, there are also certain limitations to consider regarding this systematic re-
view. Indeed, this research only considers the literature published in the English language,
thus excluding relevant studies that may have been published in other languages. Ac-
cordingly, only 10 studies published in the English language were eligible for inclusion,
whilst the small sample sizes included in these studies may reduce the reliability and
generalisability of the relevant findings. Finally, due to the small sample sizes and diverse
methodology involved in the eligible studies, a meta-analysis was not possible, and rather,
an individualised approach to conducting this systematic review was considered.
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5. Conclusions
This systematic review suggests that HBOT can impact glycaemia for people with
diabetes. Indeed, this systematic review brings together articles demonstrating the impact
of HBOT in lowering blood glucose and improving insulin sensitivity in people with type
2 diabetes mellitus. Despite these findings, there remains uncertainty as to the clinical
significance of these HBOT-induced effects on glycaemic control. There is, therefore, a need
for further research to consider the longer-term clinical impact of HBOT on glycaemia for
people with type 2 diabetes mellitus, which could be considered as a potential adjunctive
therapy to potentially improve glycaemic control in selected cases.
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Appendix A
Table A1. Demonstrating the search strategy used on the PubMed database.
Search Number Query Results
17 #15 AND #16 116
16 #3 AND #6 931
15 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 624,093
14 “hypoglycemia”[MeSH Terms] 28,951
13 hypoglycaemia[Title/Abstract] OR hypoglycemia[Title/Abstract] ORhypoglycaemic[Title/Abstract] OR hypoglycemic[Title/Abstract] 59,161
12 “hyperglycemia”[MeSH Terms] 37,247
11 hyperglycaemia[Title/Abstract] OR hyperglycemia[Title/Abstract] ORhyperglycaemic[Title/Abstract] OR hyperglycemic[Title/Abstract] 65,507
10 “glycemic control”[MeSH Terms] 270
9 glycemic[Title/Abstract] OR glycaemic[Title/Abstract] 50,821
8 “blood glucose”[MeSH Terms] 168,266
7 “blood sugar”[Title/Abstract] OR glucose[Title/Abstract] 502,819
6 #4 OR #5 16,145
5 “Hyperbaric Oxygenation”[Mesh] 12,056
4 “hyperbaric oxygen*”[Title/Abstract] OR HBO2[Title/Abstract] ORHBO[Title/Abstract] 12,164
3 #1 OR #2 729,572
2 “Diabetes Mellitus”[Mesh] 440,904
1 diabetes[Title/Abstract] OR diabetic*[Title/Abstract] 669,965
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Table A2. Demonstrating the search strategy used on the Medline database.
# Query Results
S17 S15 AND S16 113
S16 S3 AND S6 919
S15 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 597,728
S14 (MH “Hypoglycemia+”) 28,914
S13 TI (hypoglycaemia OR hypoglycemia OR hypoglycaemic OR hypoglycemic) OR AB(hypoglycaemia OR hypoglycemia OR hypoglycaemic OR hypoglycemic) 58,437
S12 (MH “Hyperglycemia+”) 37,174
S11 TI (hyperglycaemia OR hyperglycemia OR hyperglycaemic OR hyperglycemic) OR AB(hyperglycaemia OR hyperglycemia OR hyperglycaemic OR hyperglycemic) 63,950
S10 (MH “Glycemic Control”) 257
S9 TI (glycemic OR glycaemic) OR AB (glycemic OR glycaemic) 50,265
S8 (MH “Blood Glucose”) 167,965
S7 TI (“blood sugar” OR glucose) OR AB (“blood sugar” OR glucose) 473,206
S6 S4 OR S5 15,885
S5 (MH “Hyperbaric Oxygenation”) 12,048
S4 TI (“hyperbaric oxygen*” OR HBO2 OR HBO) OR AB (“hyperbaric oxygen*” OR HBO2OR HBO) 11,723
S3 S1 OR S2 727,311
S2 (MH “Diabetes Mellitus+”) 439,985
S1 TI (diabetes OR diabetic*) OR AB (diabetes OR diabetic*) 663,799
Table A3. Demonstrating the search strategy used on the Embase database.
# Query Results
17 15 and 16 199
16 3 and 6 1303
15 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 864,384
14 exp hypoglycemia/ 82,561
13 (hypoglycaemia or hypoglycemia or hypoglycaemic or hypoglycemic).ti. or(hypoglycaemia or hypoglycemia or hypoglycaemic or hypoglycemic).ab. 86,203
12 exp hyperglycemia/ 101,038
11 (hyperglycaemia or hyperglycemia or hyperglycaemic or hyperglycemic).ti. or(hyperglycaemia or hyperglycemia or hyperglycaemic or hyperglycemic).ab. 94,423
10 exp glycemic control/ 53,870
9 (glycemic or glycaemic).ti. or (glycemic or glycaemic).ab. 81,559
8 exp glucose blood level/ 260,424
7 ((blood adj1 sugar) or glucose).ti. or ((blood adj1 sugar) or glucose).ab. 658,030
6 4 or 5 14,749
5 exp hyperbaric oxygen/ or exp hyperbaric oxygen therapy/ 3230
4 ((hyperbaric adj1 oxygen*) or HBO2 or HBO).ti. or ((hyperbaric adj1 oxygen*) or HBO2or HBO).ab. 13,775
3 1 or 2 1,195,748
2 exp diabetes mellitus/ 1,014,391
1 (diabetes or diabetic*).ti. or (diabetes or diabetic*).ab. 995,738
Medicina 2021, 57, 1134 12 of 12
References
1. Mathieu, D.; Marroni, A.; Kot, J. Tenth European Consensus Conference on Hyperbaric Medicine: Recommendations for accepted
and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving Hyperb. Med. J. 2017, 47, 24–32.
[CrossRef] [PubMed]
2. Kaya, A.; Aydin, F.; Altay, T.; Karapinar, L.; Ozturk, H.; Karakuzu, C. Can major amputation rates be decreased in diabetic foot
ulcers with hyperbaric oxygen therapy? Int. Orthop. 2008, 33, 441–446. [CrossRef] [PubMed]
3. Duzgun, A.P.; Satır, H.Z.; Ozozan, O.; Saylam, B.; Kulah, B.; Coskun, F. Effect of Hyperbaric Oxygen Therapy on Healing of
Diabetic Foot Ulcers. J. Foot Ankle Surg. 2008, 47, 515–519. [CrossRef] [PubMed]
4. Flood, M. Hyperbaric oxygen therapy for diabetic foot ulcers. J. Lanc. Gen. Hosp. 2007, 2, 140–145.
5. Bhutani, S.; Vishwanath, G. Hyperbaric oxygen and wound healing. Indian J. Plast. Surg. 2012, 45, 316–324. [CrossRef] [PubMed]
6. Skyler, J.S. Effects of Glycemic Control on Diabetes Complications and on the Prevention of Diabetes. Clin. Diabetes 2004,
22, 162–166. [CrossRef]
7. Ketema, E.B.; Kibret, K.T. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control;
systematic review and meta-analysis. Arch. Public Health 2015, 73, 1–9. [CrossRef] [PubMed]
8. Heyboer III, M.; Wojcik, S.M.; Swaby, J.; Boes, T. Blood glucose levels in diabetic patients undergoing hyperbaric oxygen therapy.
Undersea Hyperb. Med. 2019, 46, 437–445.
9. Trytko, B.; Bennett, M.H. Blood sugar changes in diabetic patients undergoing hyperbaric oxygen therapy. South Pac. Underw.
Med. Soc. J. 2003, 33, 62–69.
10. Vote, D.; Ekanayake, L.; Doolette, D. Blood sugar levels and hyperbaric oxygen. South Pac. Underw. Med. Soc. J. 2001, 31, 81–82.
11. Peleg, R.K.; Fishlev, G.; Bechor, Y.; Bergan, J.; Friedman, M.; Koren, S.; Tirosh, A.; Efrati, S. Effects of hyperbaric oxygen on blood
glucose levels in patients with diabetes mellitus, stroke or traumatic brain injury and healthy volunteers: A prospective, crossover,
controlled trial. Diving Hyperb. Med. J. 2013, 43, 218–221.
12. Ekanayake, L.; Doolette, D. Effects of hyperbaric oxygen treatment on blood sugar levels and insulin levels in diabetics. South Pac.
Underw. Med. Soc. J. 2001, 31, 16–20.
13. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.;
Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71.
[CrossRef]
14. Irawan, H.; Semadi, I.N.; Widiana, I.G.R. A Pilot Study of Short-Duration Hyperbaric Oxygen Therapy to Improve HbA1c,
Leukocyte, and Serum Creatinine in Patients with Diabetic Foot Ulcer Wagner 3–4. Sci. World J. 2018, 2018, 1–6. [CrossRef]
15. Xu, Q.; Wei, Y.-T.; Fan, S.-B.; Wang, L.; Zhou, X.-P. Repetitive hyperbaric oxygen treatment increases insulin sensitivity in diabetes
patients with acute intracerebral hemorrhage. Neuropsychiatr. Dis. Treat. 2017, 13, 421–426. [CrossRef]
16. Vera-Cruz, P.; Guerreiro, F.; Ribeiro, M.J.; Guarino, M.P.; Conde, S.V. Hyperbaric Oxygen Therapy Improves Glucose Homeostasis
in Type 2 Diabetes Patients: A Likely Involvement of the Carotid Bodies. Adv. Exp. Med. Biol. 2015, 860, 221–225. [CrossRef]
[PubMed]
17. Stevens, S.L.; Narr, A.J.; Claus, P.L.; Millman, M.P.; Steinkraus, L.W.; Shields, R.C.; Buchta, W.G.; Haddon, R.; Wang, Z.; Murad,
M.H. The incidence of hypoglycemia during HBO2 therapy: A retrospective review. Undersea Hyperb. Med. 2015, 42, 191–196.
[PubMed]
18. Wilkinson, D.; Chapman, I.M.; Heilbronn, L.K. Hyperbaric oxygen therapy improves peripheral insulin sensitivity in humans.
Diabet. Med. 2012, 29, 986–989. [CrossRef] [PubMed]
19. Al-Waili, N.S.; Butler, G.J.; Beale, J.; Abdullah, M.S.; Finkelstein, M.; Merrow, M.; Rivera, R.; Petrillo, R.; Carrey, Z.; Lee, B.; et al.
Influences of Hyperbaric Oxygen on Blood Pressure, Heart Rate and Blood Glucose Levels in Patients with Diabetes Mellitus and
Hypertension. Arch. Med. Res. 2006, 37, 991–997. [CrossRef] [PubMed]
